Vivjoa FDA Approval History
Last updated by Judith Stewart, BPharm on April 29, 2022.
FDA Approved: Yes (First approved April 26, 2022)
Brand name: Vivjoa
Generic name: oteseconazole
Dosage form: Capsules
Company: Mycovia Pharmaceuticals, Inc.
Treatment for: Vaginal Yeast Infection
Vivjoa (oteseconazole) is an oral azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential.
- Recurrent vulvovaginal candidiasis (RVVC) is defined as three or more symptomatic acute episodes of yeast infection per year.
- Oteseconazole is a highly selective inhibitor of fungal CYP51 which works by inhibiting fungal growth. It is designed to have fewer side effects and improved efficacy as compared with currently available antifungal agents.
- The FDA approval for Vivjoa was based upon the positive results from three Phase 3 trials of 875 patients at 232 sites across 11 countries. In the two global VIOLET studies, 93.3% and 96.1% of women with RVVC who received Vivjoa did not have a recurrence for the 48-week maintenance period compared to 57.2% and 60.6% of patients who received placebo (p <0.001). In the U.S.-focused ultraVIOLET study, 89.7% of women with RVVC who received Vivjoa cleared their initial yeast infection and did not have a recurrence for the 50-week maintenance period compared to 57.1% of those who received fluconazole followed by placebo (p <0.001).
- Vivjoa capsules are administered orally with food. There are two recommended dosage regimens:
- Vivjoa-only regimen: once daily for 2 days then once weekly starting day 14 for 11 weeks (weeks 2 through 12)
- Fluconazole/Vivjoa regimen: Fluconazole once daily on days 1,4, and 7 then Vivjoa once daily on days 14-20, and once weekly starting day 28 for 11 weeks (weeks 4 through 14).
- Vivjoa may cause fetal harm and is contraindicated in females of reproductive potential, and in pregnant and lactating women because of potential risks to a fetus or breastfed infant.
- Common adverse reactions include headache and nausea.
Development timeline for Vivjoa
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
